RCI001AH

RCI001AH is a small molecule veterinary drug candidate being developed by RudaCure, in collaboration with the French veterinary pharmaceutical company Ceva, for the treatment of veterinary dry eye (keratoconjunctivitis sicca) in companion animals such as dogs and cats. It shares the same mechanism of action as RudaCure's human clinical candidate RCI001, acting as a modulator of the TRPV1-Rac1 downstream signaling pathway. Specifically, RCI001AH inhibits the activation of Ras-related C3 botulinum toxin substrate 1 (Rac1) and the downstream NLRP3 inflammasome/IL-1β inflammatory cascade. This targeted anti-inflammatory and antioxidant mechanism helps restore tear film homeostasis and promotes rapid corneal epithelial healing without blocking thermosensation, avoiding the side effects associated with traditional steroid therapies. Proof-of-concept studies have been completed, demonstrating superior efficacy compared to veterinary cyclosporine, and the candidate is currently preparing for veterinary clinical trials.

Other names

8-oxo-2'-deoxyguanosine8-oxo-dG